The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds； methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof； pharmaceutical compositions comprising the same； methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
